Kumagai Hozumi, Kusaba Hitoshi, Okumura Yuta, Komoda Masato, Nakano Michitaka, Tamura Shingo, Uchida Mayako, Nagata Kenichiro, Arita Shuji, Ariyama Hiroshi, Takaishi Shigeo, Akashi Koichi, Baba Eishi
Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan E-mail :
Asian Pac J Cancer Prev. 2014;15(1):461-5. doi: 10.7314/apjcp.2014.15.1.461.
Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination.
To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy.
Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups.
Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.
包括地塞米松（DEX）在内的止吐三联疗法广泛应用于接受高致吐性化疗（HEC）的患者。在日本，尚未确定该联合用药中DEX的合适剂量。
为评估增加剂量DEX的疗效和安全性，我们回顾性研究了接受HEC并采用止吐三联疗法的患者。
24例患者（福沙匹坦组）接受了增加剂量的DEX（平均总剂量：45.8mg）、福沙匹坦和5-羟色胺3（5-HT3）拮抗剂。另外48例患者（阿瑞匹坦组）接受了较低剂量的DEX（33.6mg）、口服阿瑞匹坦和5-HT3拮抗剂。福沙匹坦组和阿瑞匹坦组急性期的呕吐控制率分别为100%和85.4%，延迟期分别为75.0%和64.6%。两组的毒性发生率相似。
对于接受HEC的患者，增加剂量DEX的三联疗法被认为是安全有效的。
